Stock Track | KEYMED BIO-B Soars on NMPA Approval for Dermatitis Drug Stapokibart

Stock Track09-13

Hong Kong-based biopharmaceutical company KEYMED Biosciences Inc. (02162.HK) saw its stock soar by 6.89% on Thursday after receiving a major regulatory approval for one of its lead drug candidates.

The company announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval opens the door for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceutical market, a significant milestone for the company.

Investors reacted positively to the news, driving KEYMED's stock price up by nearly 7% in intraday trading. Analysts praised the approval as a critical step forward for the company's pipeline, with some raising their price targets and rating recommendations for the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178786344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 14:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178786344","market":"hk","top_or_hot":-1,"title":"Stock Track | KEYMED BIO-B Soars on NMPA Approval for Dermatitis Drug Stapokibart","media":"Stock Track","content":"<p>Hong Kong-based biopharmaceutical company KEYMED Biosciences Inc. (02162.HK) saw its stock soar by 6.89% on Thursday after receiving a major regulatory approval for one of its lead drug candidates.</p>\n\n<p>The company announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval opens the door for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceutical market, a significant milestone for the company.</p>\n\n<p>Investors reacted positively to the news, driving KEYMED's stock price up by nearly 7% in intraday trading. Analysts praised the approval as a critical step forward for the company's pipeline, with some raising their price targets and rating recommendations for the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | KEYMED BIO-B Soars on NMPA Approval for Dermatitis Drug Stapokibart</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | KEYMED BIO-B Soars on NMPA Approval for Dermatitis Drug Stapokibart\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-13 14:58 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hong Kong-based biopharmaceutical company KEYMED Biosciences Inc. (02162.HK) saw its stock soar by 6.89% on Thursday after receiving a major regulatory approval for one of its lead drug candidates.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1178786344","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178786344","pubTimestamp":1726210717,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hong Kong-based biopharmaceutical company KEYMED Biosciences Inc.  saw its stock soar by 6.89% on Thursday after receiving a major regulatory approval for one of its lead drug candidates.The company announced that China's National Medical Products Administration  has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval opens the door for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"NMPA批准皮炎药物Stapokibart，股票赛道KEYMED BIO-B飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Hong Kong-based biopharmaceutical company KEYMED Biosciences Inc. (02162.HK) saw its stock soar by 6.89% on Thursday after receiving a major regulatory approval for one of its lead drug candidates.\nThe company announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval opens the door for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceutical market, a significant milestone for the company.\nInvestors reacted positively to the news, driving KEYMED's stock price up by nearly 7% in intraday trading. Analysts praised the approval as a critical step forward for the company's pipeline, with some raising their price targets and rating recommendations for the stock.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178786344"}